What is the market's earnings forecast for Longeveron next quarter?

What guidance did Longeveron's management provide for the next earnings period?

What is the revenue and EPS growth rate for Longeveron year over year?

What does Longeveron do and what are its main business segments?

What were the key takeaways from Longeveron’s earnings call?

Did Longeveron beat or miss consensus estimates last quarter?

What were the key takeaways from Longeveron's earnings call?

What factors drove the changes in Longeveron's revenue and profit?

- **$15M Capital Raise**: Secured institutional backing for HLHS BLA preparation and strategic partnerships.
- **PRV Potential**: HLHS PRV sale proceeds split 50/50; PDCM PRV retained for $150-205M+ value.
- **Clinical Momentum**: ELPIS-II results Q3 2026; PDCM trial planning for 2027.
- **Financial Update**: 2025 net loss $22.7M, but $15.9M March 2026 raise extends runway to Q4 2026.
- **Strategic Focus**: Licensing Alzheimer’s/FSD, CDMO manufacturing, and PRV monetization.

**【CEO Remarks】**
- Secured $15 million in new capital from Coastlands Capital and Janus Henderson, with potential for additional $15 million upon milestones.
- Focused on completing ELPIS-II trial in HLHS (results Q3 2026) and preparing for BLA submission.
- Pursuing partnerships for Alzheimer’s, age-related frailty, and PDCM programs.
- HLHS and PDCM programs eligible for PRVs, with potential sale of HLHS PRV proceeds split 50/50 with investors.

**【CMO Clinical Update】**
- HLHS: ELPIS-II trial enrollment completed (40 patients), targeting Q3 2026 results; FDA feedback supports pivotal study designation.
- PDCM: IND approved, planning single pivotal phase 2 trial in 2027; hierarchical composite endpoint includes transplant reduction.
- Alzheimer’s: Phase 2 data to inform BLA pathway; licensing discussions underway.

**【CFO Financials】**
- 2025 revenue: $1.2 million (down 50% YoY) due to lower trial and manufacturing demand.
- Net loss: $22.7 million (up 41% YoY) driven by R&D and G&A expenses.
- $15.9 million raised in March 2026 private placement, providing runway to Q4 2026.

**【CSO Perspective】**
- Stem cell therapies validated in regenerative medicine; Longeveron’s pipeline includes 10+ patents and clinical trials in top journals.
- PDCM has no curative treatments; laromestrocel aims to reverse disease progression.

**【Q&A Highlights】**
- Manufacturing: CDMO partnership to support commercial readiness; rolling BLA submission possible post-ELPIS-II results.
- PRVs: Recent sales at $200M+; PDCM PRV entirely retained by Longeveron.
- FSD patent: Licensing strategy for indication with high unmet need in post-menopausal women.
- PDCM trial: Feasibility assessment in 2026, targeting 70 patients globally.


Longeveron LLC (LGVN) Q4 2025 Earnings Call Transcript

- **HLHS Pivotal Trial Progress**: ELPIS II enrollment complete; results expected Q3 2026, with BLA submission now targeted for 2027. 
- **Financial Challenges**: 53% revenue decline in 2025 due to reduced clinical trial demand; net loss of $17.3 million. 
- **Manufacturing Readiness**: Third-party CMO partnership established; Miami facility generates incremental revenue. 
- **Strategic Focus**: Self-commercialization for HLHS; exploring partnerships for Alzheimer's and rare pediatric indications. 
- **Regulatory Updates**: Evaluating FDA expediting programs; long-term survival data key to reimbursement.

**【CEO Summary Section】**
- Than Powell emphasized the company's focus on advancing the Phase IIb ELPIS II trial for HLHS, with enrollment completed in June 2025 and results expected in Q3 2026. 
- The company has extended its cash runway into late Q1 2026 through cost optimization and an at-the-market (ATM) equity financing facility of up to $10.7 million. 
- BLA submission for HLHS is now anticipated in 2027, delayed from late 2026 due to CMC and manufacturing readiness timelines. 
- Strategic discussions are ongoing for potential partnerships in rare pediatric diseases, with a focus on leveraging laromestrocel's mechanism of action in neuroinflammation.

**【CFO Financial Commentary】**
- Revenues for the first 9 months of 2025 decreased by 53% to $0.8 million, driven by lower demand in the Bahamas Registry Trial and contract manufacturing services. 
- Clinical trial revenue declined 36% to $0.7 million, while contract manufacturing revenue fell 76% to $0.2 million. 
- Research and development expenses increased 52% to $9.3 million, reflecting investments in CMC activities and BLA-enabling studies. 
- The company reported a net loss of $17.3 million for the period, with cash reserves of $9.2 million as of September 30, 2025. 
- The ATM facility and potential grants or collaborations are key to securing future funding.

**【CTO & CMC Update】**
- Devin Blass announced a strategic partnership with a third-party CMO for commercial manufacturing, with proof-of-concept runs completed and master services agreement in final stages. 
- Technology transfer and process validation are progressing to support BLA readiness post-ELPIS II results. 
- The Miami cGMP facility continues to generate revenue through selective contract manufacturing, offsetting clinical development costs.

**【Q&A Highlights】**
- **Partnership Strategy**: Management prioritizes self-commercialization for HLHS due to the niche market and existing surgeon network, but remains open to partnerships for non-core indications. 
- **Lewy Body Dementia**: While not currently in development, the company acknowledges neuroinflammation as a potential mechanism for laromestrocel and may explore this indication post-Alzheimer's trials. 
- **Regulatory Pathway**: The company is evaluating rolling BLA submissions and the FDA's new Commissioner's National Priority Voucher program to expedite approval. 
- **Payer Engagement**: Long-term follow-up data from ELPIS I (5-year transplant-free survival) will be critical for reimbursement discussions.

Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript

- **HLHS Milestone**: Completed enrollment for pivotal Phase 2b trial, targeting BLA submission in late 2026 if data positive.
- **Pipeline Expansion**: Secured IND for pediatric DCM, with pivotal Phase 2 trial planned for H1 2026.
- **Financial Challenges**: H1 2025 net loss widened to $10M due to higher R&D and G&A expenses, though $5M raised in August 2025 public offering.
- **Strategic Manufacturing**: Partnering with CDMO to accelerate commercial readiness and reduce capital risk.
- **Innovative Technology**: Licensed iPSC-derived cardiomyogenic cells to avoid arrhythmia risks, positioning for safer heart failure treatments.

**【CEO Summary Section】**
- Completed enrollment for pivotal ELPIS II Phase 2b study in HLHS, targeting 40 patients with 2 over-enrolled due to high demand. Top-line results expected Q3 2026.
- Secured rare pediatric disease designation for HLHS, enabling rolling BLA submission if data supports approval in late 2026.
- Expanded pipeline with pediatric dilated cardiomyopathy (DCM) IND approval, targeting a pivotal Phase 2 trial in H1 2026.
- Licensed novel iPSC-derived cardiomyogenic cells technology to address arrhythmia risks in heart treatments.

**【CFO Financial Commentary】**
- Revenues for H1 2025: $0.7M (down 31% YoY) due to lower Bahamas registry trial demand and contract manufacturing services.
- Net loss widened to $10M (H1 2025) from $7.5M (H1 2024) due to increased R&D ($5.5M vs $3.9M) and G&A ($5.5M vs $4.3M) expenses.
- Cash balance $10.3M as of Q2 2025, with $5M raised in August 2025 public offering and potential $12.5M from warrant exercises.
- Anticipate cash runway into Q1 2026, with focus on securing nondilutive funding for Alzheimer's program and CMC readiness.

**【Q&A Key Highlights】**
- **Market Dynamics**: HLHS and DCM both orphan diseases with ~1,000-1,500 new cases annually. DCM has higher prevalence (2,000-3,000 patients) due to longer survival. Pricing strategies expected to be comparable but adjusted for administration method (one-time vs chronic infusion).
- **Regulatory Pathway**: FDA agreed Phase 2 DCM trial can be pivotal if endpoints met, leveraging HLHS trial success for supportive evidence. FDA interactions remain collaborative under new administration.
- **Manufacturing Strategy**: Partnering with CDMO for commercial manufacturing to accelerate BLA readiness, reduce capital expenditure, and mitigate regulatory risks.
- **iPSC Technology**: Differentiated by selection of non-arrhythmic cardiomyogenic cells, addressing key safety concern in heart failure treatments. Preclinical studies to begin soon.

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

- **HLHS Milestone Progress**: 95% enrollment in pivotal ELPIS II trial, BLA submission on track for 2026.
- **Alzheimer's Regulatory Clarity**: FDA-approved adaptive Phase II/III trial design, partnership hunt underway.
- **Financial Challenges**: Q1 revenue down 30%, net loss up 25%, seeking additional funding for BLA readiness.
- **Commercial Potential**: HLHS market valued at $0.5B+ annually, 65% penetration target.
- **Manufacturing Strategy**: 1,500-dose capacity in-house; CDMO partnerships for scalability.


**【CEO Opening Remarks】**
- HLHS Phase IIb trial (ELPIS II) nearing completion with 95% enrollment, targeting BLA submission in 2026.
- Alzheimer's disease program secured FDA alignment for a single pivotal Phase II/III trial, seeking partnerships for funding.
- Focus on commercial readiness for HLHS, with CDMO manufacturing options under evaluation.

**【CFO Financial Update】**
- Q1 2025 revenue $0.4M (down 30% YoY) due to declining Bahamas Registry Trial participation.
- Net loss $5.0M (up 25% YoY) driven by R&D and G&A expenses.
- Cash balance $14.3M, expected to last into Q3 2025; additional funding sought for BLA activities.

**【Clinical Development Highlights】**
- HLHS: 100% transplant-free survival in Phase I, ELPIS II results to support BLA.
- Alzheimer's: Phase IIa data published in *Nature Medicine*, FDA agreed to accelerated approval pathway.

**【Q&A Key Takeaways】**
- HLHS market potential: ~$0.5B+ annually in the U.S., 65% penetration assumption.
- FDA CBER leadership changes not impacting BLA preparation; regulatory alignment maintained.
- Manufacturing strategy: in-house capacity for 1,500 doses; CDMO partnership for scale.
- PRV eligibility: contingent on congressional reauthorization, strong bipartisan support anticipated.


Longeveron (LGVN)-8 May 25-2025 Q1 Earnings call transcript

- **HLHS Trial Momentum**: 90% enrollment in pivotal ELPIS II trial, with FDA greenlight for 2026 BLA submission.
- **Alzheimer's Breakthrough**: RMAT designation for Lomecel-B, with Phase IIa data showing disease stabilization.
- **Financial Strength**: 237% revenue growth to $2.4M, 25% net loss reduction, and $19.2M cash runway to Q4 2025.
- **Strategic Focus**: Accelerated path to approval for Alzheimer's, minimal commercial infrastructure for HLHS, and CMC readiness investments.

**【Management Opening Remarks】**
- Derek Cole provided an overview of the call, highlighting the press release availability and the company's leadership team.

**【CEO Summary Section】**
- **HLHS Program Progress**: Phase IIb ELPIS II trial is 90% enrolled, with FDA confirmation as pivotal for BLA submission in 2026. HLHS market opportunity estimated at $1 billion.
- **Alzheimer's Breakthrough**: Lomecel-B received RMAT and Fast Track designations, with Phase IIa data showing disease worsening prevention. FDA meeting scheduled for March to discuss accelerated path.
- **INN Name Approval**: Laromestrocel received WHO international non-proprietary name, advancing commercial readiness.

**【CMO Clinical Update】**
- **HLHS Enrollment Challenges**: Surgery timing delays caused enrollment delays, but 35/38 patients enrolled. FDA open to composite endpoints (e.g., RVEF, hospitalization) for 12-month follow-up.
- **Alzheimer's Regulatory Momentum**: RMAT designation positions Lomecel-B for accelerated approval. Global partnership discussions underway post-BLA submission.

**【CFO Financial Commentary】**
- **Revenue Growth**: 2024 revenue $2.4M (+237%), driven by contract manufacturing ($1M) and registry trial demand.
- **Cost Efficiency**: Operating expenses down 13% to $18.4M, with R&D (-10%) and G&A (-16%) reductions. Net loss reduced 25% to $16M.
- **Cash Position**: $19.2M as of Q4, sufficient for operations into Q4 2025. BLA readiness activities expected to accelerate 2025 spend, requiring additional funding.

**【Q&A Highlights】**
- **ELPIS II Enrollment**: Final 3-5 patients expected by Q2 2025, with no new sites needed. Top-line results anticipated summer 2026.
- **Commercial Strategy**: Minimal infrastructure (2-3 sales reps) for HLHS due to 50 U.S. surgeons. Alzheimer's focus on partnerships post-BLA.
- **Manufacturing Outlook**: Steady contract revenue ($1M in 2024), with CMC readiness prioritized for BLA submission.
- **Regulatory Strategy**: Seeking PRV extension for HLHS. No international Alzheimer's interactions yet; U.S. focus first.


Actual				-2.5	-2	-1.7	-2.7	-2.5	-2.1	-2.2	-2.7	-2.8	-2.5	-1.61	-1.83	-0.34	-0.4338	-0.34	-0.33	-0.39	-0.23
Forecast					-2.5	-2.25	-2.2667	-2.2	-2	-2.1333	-2.4667	-2.25	-2.1333	-2.005	-0.87	-0.4433	-0.3567	-0.3275	-0.35	-0.255	-0.3667
Surprise	0.00%	0.00%	0.00%	0.00%	+20.00%	+24.44%	-19.12%	-13.64%	-5.00%	-3.13%	-9.46%	-24.44%	-17.19%	+19.70%	-110.34%	+23.30%	-21.61%	-3.82%	+5.71%	-52.94%	+37.28%

LGVN

LGVN fundamentals

LGVN Q4 2025 Earnings

Earnings Call

You can ask Aime

LGVN

LGVN fundamentals

LGVN Q4 2025 Earnings

Earnings Call

LGVN Earnings Call Summary for Q4/20254:30 PM on Mar 17, 2026

LGVN Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

LGVN Earnings Call Summary for Q2/20254:30 PM on Aug 13, 2025

LGVN Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

LGVN Earnings Call Summary for Q4/20244:30 PM on Feb 28, 2025

You can ask Aime